Home/Filings/4/0001209191-18-024986
4//SEC Filing

LOAR MATTHEW M 4

Accession 0001209191-18-024986

CIK 0000908259other

Filed

Apr 15, 8:00 PM ET

Accepted

Apr 16, 4:22 PM ET

Size

10.6 KB

Accession

0001209191-18-024986

Insider Transaction Report

Form 4
Period: 2018-04-12
LOAR MATTHEW M
Chief Financial Officer
Transactions
  • Purchase

    Common Stock A Warrant (Right to Buy)

    2018-04-12+125,000125,000 total
    Exercise: $0.40From: 2018-04-12Exp: 2020-04-12Common Stock (125,000 underlying)
  • Purchase

    Common Stock

    2018-04-12+250,000300,000 total
  • Purchase

    Common Stock B Warrant (Right to Buy)

    2018-04-12+125,000125,000 total
    Exercise: $0.40Common Stock (125,000 underlying)
Footnotes (3)
  • [F1]The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share.
  • [F2]The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date").
  • [F3]The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years.

Issuer

MATEON THERAPEUTICS INC

CIK 0000908259

Entity typeother

Related Parties

1
  • filerCIK 0001236260

Filing Metadata

Form type
4
Filed
Apr 15, 8:00 PM ET
Accepted
Apr 16, 4:22 PM ET
Size
10.6 KB